{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:09Z","timestamp":1792931829338,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ck0106251h0003"],"award-info":[{"award-number":["22ck0106251h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s12185-023-03677-w","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T14:02:25Z","timestamp":1701180145000},"page":"24-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-4470","authenticated-orcid":false,"given":"Kensuke","family":"Usuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumihisa","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Sezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Tomikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Mugitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kajiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Asou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Katsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"3677_CR1","unstructured":"NCI Cancer Stats. Acute myeloid leukemia\u2014cancer stat facts. @NCICancerStats; 2023."},{"key":"3677_CR2","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","volume":"5","author":"A Miranda-Filho","year":"2018","unstructured":"Miranda-Filho A, Pi\u00f1eros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018;5:e14\u201324.","journal-title":"Lancet Haematol"},{"key":"3677_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536\u201345.","journal-title":"Br J Haematol"},{"key":"3677_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"key":"3677_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3324\/haematol.2010.026252","volume":"96","author":"M Maynadi\u00e9","year":"2011","unstructured":"Maynadi\u00e9 M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F, et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d\u2019Or (Burgundy, France). Haematologica. 2011;96:55\u201361.","journal-title":"Haematologica"},{"key":"3677_CR6","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724\u201334.","journal-title":"Blood"},{"key":"3677_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/leu.2015.188","volume":"30","author":"AG Dinmohamed","year":"2016","unstructured":"Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, et al. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989\u20132012. Leukemia. 2016;30:24\u201331.","journal-title":"Leukemia"},{"key":"3677_CR8","first-page":"1400","volume":"91","author":"KJ Phekoo","year":"2006","unstructured":"Phekoo KJ, Richards MA, M\u00f8ller H, Schey SA. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica. 2006;91:1400\u20134.","journal-title":"Haematologica"},{"key":"3677_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.2012.064014","volume":"98","author":"M Maynadi\u00e9","year":"2013","unstructured":"Maynadi\u00e9 M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98:230\u20138.","journal-title":"Haematologica"},{"key":"3677_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3324\/haematol.2012.063602","volume":"98","author":"D Pulte","year":"2013","unstructured":"Pulte D, Redaniel MT, Jansen L, Brenner H, Jeffreys M. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica. 2013;98:222\u20139.","journal-title":"Haematologica"},{"key":"3677_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931\u201342.","journal-title":"Lancet Oncol"},{"key":"3677_CR12","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.ejca.2015.08.003","volume":"51","author":"R De Angelis","year":"2015","unstructured":"De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000\u20132007: results of EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2254\u201368.","journal-title":"Eur J Cancer"},{"key":"3677_CR13","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SCE Swerdlow","year":"2008","unstructured":"Swerdlow SCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: WHO Press; 2008.","edition":"4"},{"key":"3677_CR14","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","volume":"98","author":"D Grimwade","year":"2001","unstructured":"Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312\u201320.","journal-title":"Blood"},{"key":"3677_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"3677_CR16","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","volume":"96","author":"ML Slovak","year":"2000","unstructured":"Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075\u201383.","journal-title":"Blood"},{"key":"3677_CR17","first-page":"901","volume-title":"Trial to extract prognostic factors prior to the start of induction chemotherapy for adult AML","author":"K Kuriyama","year":"1998","unstructured":"Kuriyama K, Tomonaga M, Kobayashi T, Nishikawa K, Ohsima T, Furusawa S, et al. Trial to extract prognostic factors prior to the start of induction chemotherapy for adult AML. Berlin, Heidelberg: Springer; 1998. p. 901\u20135."},{"key":"3677_CR18","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1002\/cncr.21493","volume":"104","author":"S Miyawaki","year":"2005","unstructured":"Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer. 2005;104:2726\u201334.","journal-title":"Cancer"},{"key":"3677_CR19","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","volume":"117","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood. 2011;117:2358\u201365.","journal-title":"Blood"},{"key":"3677_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12185-012-1105-y","volume":"96","author":"A Wakita","year":"2012","unstructured":"Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, et al. Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 study. Int J Hematol. 2012;96:84\u201393.","journal-title":"Int J Hematol"},{"key":"3677_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2006-08-043992","volume":"110","author":"N Asou","year":"2007","unstructured":"Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110:59\u201366.","journal-title":"Blood"},{"key":"3677_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3677_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.7326\/0003-4819-103-3-460","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French\u2013American\u2013British Cooperative Group. Ann Intern Med. 1985;103:460\u20132.","journal-title":"Ann Intern Med"},{"key":"3677_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French\u2013American\u2013British Cooperative Group. Ann Intern Med. 1985;103:620\u20135.","journal-title":"Ann Intern Med"},{"key":"3677_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2141.1991.tb04444.x","volume":"78","author":"JM Bennett","year":"1991","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol. 1991;78:325\u20139.","journal-title":"Br J Haematol"},{"key":"3677_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/bjc.1996.354","volume":"74","author":"M Maynadi\u00e9","year":"1996","unstructured":"Maynadi\u00e9 M, Verret C, Moskovtchenko P, Mugneret F, Petrella T, Caillot D, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996;74:288\u201390.","journal-title":"Br J Cancer"},{"key":"3677_CR27","first-page":"905","volume":"89","author":"U Germing","year":"2004","unstructured":"Germing U, Strupp C, K\u00fcndgen A, Bowen D, Aul C, Haas R, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004;89:905\u201310.","journal-title":"Haematologica"},{"key":"3677_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","volume":"112","author":"DE Rollison","year":"2008","unstructured":"Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs. Blood. 2008;112:45\u201352.","journal-title":"Blood"},{"key":"3677_CR29","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","volume":"117","author":"CR Cogle","year":"2011","unstructured":"Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117:7121\u20135.","journal-title":"Blood"},{"key":"3677_CR30","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","volume":"35","author":"J Neukirchen","year":"2011","unstructured":"Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, et al. Incidence and prevalence of myelodysplastic syndromes: data from the D\u00fcsseldorf MDS-registry. Leuk Res. 2011;35:1591\u20136.","journal-title":"Leuk Res"},{"key":"3677_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2188\/jea.JE20140042","volume":"24","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Sobue T, et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24:469\u201373.","journal-title":"J Epidemiol"},{"key":"3677_CR32","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ejca.2013.12.002","volume":"50","author":"AG Dinmohamed","year":"2014","unstructured":"Dinmohamed AG, Visser O, van Norden Y, Huijgens PC, Sonneveld P, van de Loosdrecht AA, et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer. 2014;50:1004\u201312.","journal-title":"Eur J Cancer"},{"key":"3677_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/bjh.13414","volume":"171","author":"AG Dinmohamed","year":"2015","unstructured":"Dinmohamed AG, Brink M, Visser O, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M, et al. Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012. Br J Haematol. 2015;171:436\u20139.","journal-title":"Br J Haematol"},{"key":"3677_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.leukres.2014.11.025","volume":"39","author":"AG Dinmohamed","year":"2015","unstructured":"Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk Res. 2015;39:177\u201382.","journal-title":"Leuk Res"},{"key":"3677_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","volume":"34","author":"AM Zeidan","year":"2019","unstructured":"Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1\u201315.","journal-title":"Blood Rev"},{"key":"3677_CR36","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","volume":"28","author":"SL Goldberg","year":"2010","unstructured":"Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847\u201352.","journal-title":"J Clin Oncol"},{"key":"3677_CR37","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1182\/bloodadvances.2020003381","volume":"5","author":"J Rozema","year":"2021","unstructured":"Rozema J, Hoogendoorn M, Kibbelaar R, van den Berg E, Veeger N, van Roon E. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study. Blood Adv. 2021;5:1344\u201351.","journal-title":"Blood Adv"},{"key":"3677_CR38","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1200\/JCO.2017.73.6728","volume":"35","author":"LSG \u00d8stg\u00e5rd","year":"2017","unstructured":"\u00d8stg\u00e5rd LSG, N\u00f8rgaard M, Medeiros BC, Friis LS, Schoellkopf C, Severinsen MT, et al. Effects of education and income on treatment and outcome in patients with acute myeloid leukemia in a tax-supported health care system: a national population-based cohort study. J Clin Oncol. 2017;35:3678\u201387.","journal-title":"J Clin Oncol"},{"key":"3677_CR39","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179\u201387.","journal-title":"Blood"},{"key":"3677_CR40","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1200\/JCO.2013.53.3570","volume":"32","author":"K Shinagawa","year":"2014","unstructured":"Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol. 2014;32:3729\u201335.","journal-title":"J Clin Oncol"},{"key":"3677_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41408-022-00654-0","volume":"12","author":"KH Begna","year":"2022","unstructured":"Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, et al. Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with \u201c7+3.\u201d Blood Cancer J. 2022;12:55.","journal-title":"Blood Cancer J"},{"key":"3677_CR42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/bjh.17523","volume":"194","author":"PH Wiernik","year":"2021","unstructured":"Wiernik PH, Sun Z, Cripe LD, Rowe JM, Fernandez HF, Luger SM, et al. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. Br J Haematol. 2021;194:309\u201318.","journal-title":"Br J Haematol"},{"key":"3677_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41408-022-00736-z","volume":"12","author":"F Rapaport","year":"2022","unstructured":"Rapaport F, Seier K, Neelamraju Y, Hassane D, Baslan T, Gildea DT, et al. Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group\u2019s clinical trial E3999. Blood Cancer J. 2022;12:137.","journal-title":"Blood Cancer J"},{"key":"3677_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41408-023-00850-6","volume":"13","author":"JR Hilberink","year":"2023","unstructured":"Hilberink JR, van Zeventer IA, Chitu DA, Pabst T, Klein SK, Stussi G, et al. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood Cancer J. 2023;13:93.","journal-title":"Blood Cancer J"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03677-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03677-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03677-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T13:17:11Z","timestamp":1704460631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03677-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3677"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03677-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"25 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kensuke Usuki has received research funding from Astellas, AbbVie, Bristol-Myers Squibb, Janssen, Ono, Otsuka, Chugai, Aperis, Yakult, MSD, Amgen, Alxion, Incyte, Eisai, Kyowa-Kirin, Sanofi, SymBio, Celgene, Daichi Sankyo, Sumitomo-Dainippon, Nippon Shinyaku, Novartis, Mundi, and Takeda, has served on speaker bureaus for Novartis, Abbvie, Alexion, Incyte, Ono, Kyowa-Kirin, Sanofi, Takeda, Nippon-Shinyaku, Pfizer, and Bristol-Myers Squibb, and has served on consulting bureaus for Astellas, Amgen, Alnylam Japan, Alexion, Eisai, Otsuka, Ohara, Kyowa-Kirin, Sanofi, Sando, SymBio, Takeda, Chugai, and Nippon Shinyaku; Hisayuki Yokoyama has served on speaker bureaus for Astellas Pharma; Hiroshi Handa received research funding from Kyowa-Kirin Pharmaceutical, Chugai Pharmaceutical, and Dai-ich Sankyo; Shuichi Ota1 has served on speaker bureaus for Novartis, Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, AstraZeneca, Janssen Pharmaceutical K.K., and Abbvie; Katsumichi Fujimaki has served on speaker bureaus for Otsuka Pharmaceuticals; Kensuke Kojima has served on speaker bureaus for Janssen, AstraZeneca, and Abbvie; Tomohiro Kajiguchi has served on speaker bureaus for Janssen Pharmaceutical, Novartis, Otsuka Pharmaceutical, Ono Pharmaceutical, Nippon Shinyaku, Sanofi, Abbvie, Pfizer, Bristol-Myers Squibb, Kyowa-Kirin, Chugai Pharmaceutical, AstraZeneca, Takede Pharmaceuticals, and Mundipharma; Norio Asou received research funding from Chugai Pharmaceutical, Sumitomo Dainippon Pharma, and Eisai and has served on Advisory Board for Nippon Shinyaku, and Novartis Pharma; Noriko Usui has served on speaker bureaus for Nippon Shinyaku, AbbVie, and Daiichi Sankyo, and has served on consulting bureaus for CMIC Co., Ltd.; Itaru Matsumura received research funding from Ono Pharmaceutical, Janssen Pharmaceutical, Nippon Shinyaku, Kyowa-Kirin, Sumitomo Dainippon Pharma, Shionogi, Teijin Pharma, Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical, Eisai, MSD, Asahi Kasei Pharma, Astellas Pharma, Takeda Pharmaceutical, Nihon Pharmaceutical, Daiichi Sankyo, AbbVie, Taiho Pharaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, CSL Behring, Mundipharma, Ayumi Pharmaceutical, Eli Lilly Japan, Actelion Pharmaceuticals Japan, and Amgen BioPharma, has served on speaker bureaus for Bristol-Myers Squibb (Celgene), Novartis Pharmaceuticals, Otsuka Pharmaceutical, Pfizer Japan, Janssen Pharmaceutical, Astellas Pharma, Takeda Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, SymBio Pharmaceuticals, AbbVie, Amgen BioPharma, and has served on consulting bureaus for Otsuka Pharmaceutical; Yasushi Miyazaki has served on speaker bureaus for ovartis, Abbvie, Nppon-Shinyaku, Astellas, Sumitomo Pharma, and Synbio; Shigeki Ohtake, Sumihisa Honda, Mitsuhiro Matsuda, Atsushi Wakita, Yuichiro Nawa, Ken Takase, Akio Maeda, Nobuo Sezaki, Satoru Takada, Daiki Hirano, Tatsuki Tomikawa, Masahiko Sumi, Shingo Yano, Hiroyuki Fujita, Atsuko Mugitani, Ko Fujimoto, Yuichi Ishikawa, Akira Katsumi, Hitoshi Kiyoi have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}